Beta-receptor blocking drugs are known to decrease BP and plasma renin activity (PRA) in hypertensive patients. We treated 31 hypertensive patients with the beta-receptor blocking drug, pindolol, for 3 months. During the first month (mean daily dose 10 mg) and the second month (mean daily dose 14.2 mg) BP and PRA decreased. During the third month of pindolol therapy (mean daily dose 19.0 mg) 16 patients had an unexpected rise of BP towards control levels and PRA levels rose, too. The remaining 15 patients maintained a good antihypertensive drug effect and suppression of PRA. Pretreatment PRA was not related to BP reduction. The change in diastolic BP was not significantly related to that in PRA. The results indicate that low doses of pindolol,10-15 mg daily, will suffice in mild essential hypertension. An increasing frequency of partial drug resistance may be a result of unnecessarily high doses of pindolol.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.0954-6820.1977.tb16783.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Intravenous Patient-Controlled Analgesia for Cancer Pain: A Randomized Controlled Trial on Adjusted Background Infusion Rates.
JCO Oncol Pract
January 2025
Division of Medical Oncology, Yonsei Cancer Center, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Purpose: Patient-controlled analgesia (PCA) has been considered for managing cancer pain; however, limited research has been conducted on optimizing continuous infusion rates with PCA. This study aimed to evaluate the efficacy and safety of a method that optimizes background infusion (BI) alongside PCA for titrating intravenous (IV) morphine in managing cancer-related pain.
Methods: Forty-four patients with solid tumors who could not manage pain with oral or transdermal opioid analgesics were randomly assigned in a 1:1 ratio to receive IV morphine through PCA or the conventional method.
SAFETY, PHARMACOKINETICS, AND CLINICAL EFFICACY OF ADS051, A NEUTROPHIL MODULATOR, IN ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED PHASE 1B TRIAL.
Am J Gastroenterol
December 2024
Adiso Therapeutics, Inc, Concord, Massachusetts, USA.
Objectives: Ulcerative colitis (UC) is characterized by colonic inflammation, with neutrophils playing a key role in UC activity, prognosis, and response to therapies. Current UC therapeutics can have significant side effects and limited efficacy. ADS051 is a novel, oral, gut-restricted small molecule that modulates neutrophil migration and activation without in vitro suppression of T-cell activation.
View Article and Find Full Text PDFTAK-994 Mechanistic Investigation into Drug-Induced Liver Injury.
Toxicol Sci
January 2025
Takeda Development Center Americas, Inc, Cambridge, MA, USA.
The frequency of drug-induced liver injury (DILI) in clinical trials remains a challenge for drug developers despite advances in human hepatotoxicity models and improvements in reducing liver-related attrition in preclinical species. TAK-994, an oral orexin receptor 2 agonist, was withdrawn from phase II clinical trials due to the appearance of severe DILI. Here, we investigate the likely mechanism of TAK-994 DILI in hepatic cell culture systems examined cytotoxicity, mitochondrial toxicity, impact on drug transporter proteins, and covalent binding.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
School of Biomedical Engineering, ShanghaiTech University, Shanghai, China.
Background: About 50-90% people with dementia would develop behavioral disturbances, namely, behavioral and psychological symptoms of dementia (BPSD). Antipsychotic medications are widely used to control severe BPSD symptoms which suffers serious safety risks. It is challenge for individualized precise prediction of antipsychotic drug doses.
View Article and Find Full Text PDFSafety and efficacy of three alternative regimens against relapsing Plasmodium vivax malaria in glucose 6-phosphate dehydrogenase deficient patients in the Brazilian Amazon (ALTPRIM).
Clin Infect Dis
January 2025
Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil.
Background: Daily primaquine-induced hemolysis is a common cause of complications during Plasmodium vivax malaria treatment in individuals with glucose 6-phosphate dehydrogenase deficiency (G6PDd). Alternative regimens balancing safety and efficacy are needed.
Methods: G6PDd participants with P.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!